Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $14.25-$15.25 vs $15.62 analyst estimate.

Biogen is updating its guidance for full year 2026 to reflect an approximately $1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy. This comprises approximately $0.20 recorded in the first quarter and approximately $0.80 expected in the second quarter. This